In yesterday’s trading session, the share price of Pharmacyte Biotech Inc (OTCMKTS:PMCB) registered a new 52-week low. The stock declined 8.63% to stop at $0.0720 per share on massive share volume of 6.75 million compared to monthly average share volume of 1.48 million.
Pharmacyte issued as many as four press releases in this month but they hardly did anything to boost investor confidence in the PMCB stock. The company last reported of taking initiatives towards moving into Phase IIb studies. Even though the first press release emphasized that the company commences Phase 2b trial push, it reported the first step in a string of events that would direct it to the actual Phase IIb clinical stage.
A couple of days ago Pharmacyte published an article authored by its Chief Executive Dr. Gerald W. Crabtree. Explaining the “Cell-in-a-Box®” technology, the CEO said that live-cell encapsulation know-how does not deliver and encapsulate medication to treat pancreatic cancer. It is a unique technology that encapsulates genetically modified living cells in protective cocoons. The outer cover is made of cotton, or to be more precise cellulose. These cocoons are not designed to, and cannot be utilized to put in small molecules.
Nutra Pharma Corp. (OTCMKTS:NPHC) Updates On RPI-78M Drug Status
Nutra Pharma Corp. (OTCMKTS:NPHC) stated that its lead drug RPI-78M has obtained Orphan Drug designation. The drug under focus is meant for the treatment of Multiple Sclerosis in children. The company operates as a biotech entity marketing Nyloxin® and Pet Pain-Away, and advancing drugs for Adrenomyeloneuropathy, MS and Human Immunodeficiency Virus treatment. Rik J. Deitsch, the CEO said that obtaining FDA Orphan Drug Designation is a significant achievement for the company.
Natural Alternatives International, Inc. (NASDAQ:NAII) announced that the net sales came at $79.5million and net income stood at $3.3million for the year competed June 30, 2015.